Release date: 2017-04-01
Researchers believe that lung probes used to diagnose bacterial infections can prevent unnecessary antibiotic use in the intensive care unit.
The fiber optic tube can show if the patient needs medication for treatment within 60 seconds.
It is hoped that the Proteus Proteus technology will solve the problem of bacterial resistance to antibiotics.
The project was developed by Heriot-Watt and Bath, scientists at the University of Edinburgh.
Proteus technology has received £2 million in funding from the ConocoPhillips Trust.
Proteus technology will also be greatly enhanced by receiving nearly £1 million from the CARB-X antibiotic resistance research project funded by the US government and ConocoPhillips Trust.
When Proteus attaches to a specific type of infected bacterium, the chemicals they use brighten.
The fiber tube used to detect fluorescence is small enough to be deeply buried in the patient's lungs.
"Potential side effects"
The research team hopes the technology will "completely change the way in which critical patients and other patients with long-term lung disease are evaluated and treated."
Currently, doctors mostly rely on X-rays and blood tests to make a diagnosis, but these tests may be too slow and not very accurate.
Patients often use antibiotics as a precaution to expose them to potential side effects of antibiotics.
Dr. Kev Dhaliwal, who led the technology project at the University of Edinburgh, said: "We need to better understand the patient's condition so that we can make better decisions at the bedside."
“This Proteus project and clinical partners, bringing together scientists and clinicians from many disciplines in all corners of the UK, have developed new technologies that can help us detect diseases in real time at the bedside and help us in the right place. The time to give the right treatment.
“The emergence of antibiotic resistance is the biggest challenge facing modern medicine. The financial support from CARB-X will accelerate the development preparation of Proteus technology, making it faster in clinical use than before. wide."
Tim Jinks of the Wellcome Trust said: “Drug-resistant infections have become a particularly serious global health challenge – and this situation will get worse.â€
“We need forces from all over the world to work together in many ways – from the drug development and diagnostic development channels to the end.â€
Http://
Source: Noble
Our company specializes in providing Nootropics raw materials -Nootropics Nootropics Nootropics powder Nootropic Active Pharmaceutical Ingredients Nootropics peptides
We also provide Active Pharmaceutical Ingredients // Bodybuilding Peptide //Sarms and so on
Nootropics , Nootropics powder , Nootropic Active Pharmaceutical Ingredients , Nootropics peptides
XI AN RHINE BIOLOGICAL TECHNOLOGY CO.,LTD , https://www.xianrhinebiotech.com